ˈɑːntɹɪktˌɪnɪb fˈɔːɹmɚli ˌɑːɹɹˌɛksdˌiːˈɛks wˈʌnhˈʌndɹɪd wˈʌn ɪz ɐn ɪnvˌɛstɪɡˈeɪʃənəl dɹˈʌɡ dɪvˈɛləpt baɪ ˈɪɡnɪɾə, ˈɪŋk., wˌɪtʃ hɐz pətˈɛnʃəl ˌæntɪtˈuːmɚɹ æktˈɪvᵻɾi.
Entrectinib (formerly RXDX-101) is an investigational drug developed by Ignyta, Inc., which has potential antitumor activity.